Cargando…

Engineering therapeutic protein disaggregases

Therapeutic agents are urgently required to cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Alzheimer’s disease (AD). Protein disaggregases that reverse protein misfol...

Descripción completa

Detalles Bibliográficos
Autor principal: Shorter, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Cell Biology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865313/
https://www.ncbi.nlm.nih.gov/pubmed/27255695
http://dx.doi.org/10.1091/mbc.E15-10-0693
_version_ 1782431771225227264
author Shorter, James
author_facet Shorter, James
author_sort Shorter, James
collection PubMed
description Therapeutic agents are urgently required to cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Alzheimer’s disease (AD). Protein disaggregases that reverse protein misfolding and restore proteins to native structure, function, and localization could mitigate neurodegeneration by simultaneously reversing 1) any toxic gain of function of the misfolded form and 2) any loss of function due to misfolding. Potentiated variants of Hsp104, a hexameric AAA+ ATPase and protein disaggregase from yeast, have been engineered to robustly disaggregate misfolded proteins connected with ALS (e.g., TDP-43 and FUS) and PD (e.g., α-synuclein). However, Hsp104 has no metazoan homologue. Metazoa possess protein disaggregase systems distinct from Hsp104, including Hsp110, Hsp70, and Hsp40, as well as HtrA1, which might be harnessed to reverse deleterious protein misfolding. Nevertheless, vicissitudes of aging, environment, or genetics conspire to negate these disaggregase systems in neurodegenerative disease. Thus, engineering potentiated human protein disaggregases or isolating small-molecule enhancers of their activity could yield transformative therapeutics for ALS, PD, and AD.
format Online
Article
Text
id pubmed-4865313
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The American Society for Cell Biology
record_format MEDLINE/PubMed
spelling pubmed-48653132016-07-30 Engineering therapeutic protein disaggregases Shorter, James Mol Biol Cell MBoC Perspective on Cell Biology and Human Health Therapeutic agents are urgently required to cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Alzheimer’s disease (AD). Protein disaggregases that reverse protein misfolding and restore proteins to native structure, function, and localization could mitigate neurodegeneration by simultaneously reversing 1) any toxic gain of function of the misfolded form and 2) any loss of function due to misfolding. Potentiated variants of Hsp104, a hexameric AAA+ ATPase and protein disaggregase from yeast, have been engineered to robustly disaggregate misfolded proteins connected with ALS (e.g., TDP-43 and FUS) and PD (e.g., α-synuclein). However, Hsp104 has no metazoan homologue. Metazoa possess protein disaggregase systems distinct from Hsp104, including Hsp110, Hsp70, and Hsp40, as well as HtrA1, which might be harnessed to reverse deleterious protein misfolding. Nevertheless, vicissitudes of aging, environment, or genetics conspire to negate these disaggregase systems in neurodegenerative disease. Thus, engineering potentiated human protein disaggregases or isolating small-molecule enhancers of their activity could yield transformative therapeutics for ALS, PD, and AD. The American Society for Cell Biology 2016-05-15 /pmc/articles/PMC4865313/ /pubmed/27255695 http://dx.doi.org/10.1091/mbc.E15-10-0693 Text en © 2016 Shorter. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0). “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.
spellingShingle MBoC Perspective on Cell Biology and Human Health
Shorter, James
Engineering therapeutic protein disaggregases
title Engineering therapeutic protein disaggregases
title_full Engineering therapeutic protein disaggregases
title_fullStr Engineering therapeutic protein disaggregases
title_full_unstemmed Engineering therapeutic protein disaggregases
title_short Engineering therapeutic protein disaggregases
title_sort engineering therapeutic protein disaggregases
topic MBoC Perspective on Cell Biology and Human Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865313/
https://www.ncbi.nlm.nih.gov/pubmed/27255695
http://dx.doi.org/10.1091/mbc.E15-10-0693
work_keys_str_mv AT shorterjames engineeringtherapeuticproteindisaggregases